Randomized trial demonstrates craniofacial defects in mice following Smoothened Agonist exposure, indicating significant developmental risks.
Objective While inhibition of Hedgehog (Hh) signalling is known to cause cleft lip, the effects of its hyperactivation on craniofacial development remain systematically unexplored. Materials and methods Pregnant mice received a single intraperitoneal injection of Smoothened Agonist (SAG) (25 mg/kg) at various time points between E7.5 and E12.5. A median cleft lip model was established at E10.5. Mechanisms were assessed by analysing cell proliferation (PHH3, Ki67), apoptosis (TUNEL), and expression of cell cycle regulators (Cyclin A, B1, D1, E1). Results SAG administration induced craniofacial defects – including cranial bone abnormalities, hematomas, and cleft lip/palate – in a time-dependent manner. The critical window for cleft lip induction was E9.5–E10.5. Mechanistically, SAG-induced cleft lip was associated with reduced proliferation and altered expression of selected cell-cycle markers, consistent with delayed G0/G1 progression. No significant change in apoptosis was observed. Conclusion SAG is a potent teratogen that can induce cleft lip during a critical developmental window, potentially through suppression of cell proliferation and perturbation of cell-cycle progression. While its prenatal use poses significant risks, SAG also provides a useful experimental tool for generating congenital craniofacial defect models.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: